Combination of Radioligand Therapy and Immunotherapy: How to Make It Work in Clinic?
Rubin Jiao, Ekaterina Dadachova College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, CanadaCorrespondence: Ekaterina Dadachova, College of Pharmacy and Nutrition, University of Saskatchewan, 107 Wiggins Road, Health Sciences Bld, Room B18, Saskatoon, SK, S7N 5E5, Canada, Tel...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-07-01
|
| Series: | ImmunoTargets and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/combination-of-radioligand-therapy-and-immunotherapy-how-to-make-it-wo-peer-reviewed-fulltext-article-ITT |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Rubin Jiao, Ekaterina Dadachova College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, CanadaCorrespondence: Ekaterina Dadachova, College of Pharmacy and Nutrition, University of Saskatchewan, 107 Wiggins Road, Health Sciences Bld, Room B18, Saskatoon, SK, S7N 5E5, Canada, Tel +1-306-966-5163, Email ekaterina.dadachova@usask.caAbstract: Combining external beam radiation therapy (EBRT) with immunotherapy showed promise pre-clinically by inducing immunogenic cell death (ICD) thus releasing damage-associated molecular patterns (DAMPs) and cytokines to activate the immune system. Clinical results, however, have often been disappointing. Radioligand therapy (RL), which uses targeted radionuclides to deliver cytotoxic radiation, offers advantages over EBRT by treating multiple tumors simultaneously. Combining RL with immunotherapy faces challenges, as prolonged radiation exposure can damage immune cells, and the “cross-fire” and “bystander” effects may harm incoming effector cells. Current RL therapies require multiple doses, further complicating immune cell viability. To optimize RL-immunotherapy combinations, timing is critical. Administering immunotherapy weeks after RL therapy may reduce radiation-induced immune cell damage. Additionally, selecting radionuclides with shorter half-lives could minimize immune cell toxicity while maintaining tumor-killing efficacy. Future RL therapies should prioritize radionuclides with optimal emission profiles and half-lives to enhance synergy with immunotherapy and improve clinical outcomes.Keywords: immunotherapy, radioligand therapy, combination therapy, clinical outcomes, radiobiology |
|---|---|
| ISSN: | 2253-1556 |